Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171) STA

5th Appraisal committee meeting, 23 March 2017 **Lead team**: John Cairns, John Pounsford, Matthew Campbell-Hill

Company: Celgene

NICE team: Mary Hughes, Jasdeep Hayre, Rosie Lovett, Carl Prescott, Abi Senthinathan, Melinda Goodall

Evidence Review Group: PenTAG with Matrix

Chair: Amanda Adler

Key issues for consideration

- Do the Committee's conclusions remain the same for:
 - Comparators (melphalan, bortezomib)?
 - Modelling approach (crude or proxy)?
- Is there an unmet need?

Lenalidomide (Revlimid)


 Marketing authorisation: combined with dexamethasone for adults who had at least 1 prior therapy*

History of TA171			
2009	 Lenalidomide recommended after ≥ 2 therapies PAS: company pays for treatment after 26 cycles of treatment 		
2012	 NICE decides to review lenalidomide after 1 prior therapy with bortezomib Rationale: treatment pathway changed & new evidence 		


* In 2015: the marketing authorisation was extended to include lenalidomide monotherapy for adult patients with previously untreated multiple myeloma who are not eligible for transplant. This will be considered in a NICE technology appraisal (ID474), which is currently suspended

Multiple myeloma treatment pathway

for people unsuitable for stem cell transplantation with high dose chemotx



History of this appraisal



Decision problem

	NICE scope	Company decision problem			
Pop.	5	Its with myeloma contraindicated to thalidomide whose disease gressed after bortezomib (+ not for stem cell transplant)			
Comp.	 Chemotherapy: melpha vincristine, cyclophosph doxorubicin Bortezomib Monotherapy + dexamethasone Bendamustine 				
Outcomes	 Progression-free surviv Response rates Time to next treatment Mortality Adverse effects of treat Health-related quality of 	treatment (not reported in main trial)mentBortezomib retreatment			
Subgroups	None Committee conclud later in treatment pa not a compara	ed taken $$ Discussed at $3^{rd} + 4^{th}$ meeting. athway \rightarrow Consultation comments			

6

Sources of clinical evidence: survival

No trials comparing lenalidomide with chemotherapy

	Lenalidomide		Chemotherapy
Analysis	Pooled 2 RCTs MM009/10		Petrucci et al 1989
Population	About 35% of patients had 1 prior therapy and about 65% had had at least 2 prior therapies		Patients with disease relapsed or refractory to chemotherapy. # of prior therapies was not reported
Treatment	Lenalidomide + dexamethasone n=353	Placebo + dexamethasone n=351	Melphalan + prednisolone n=34
1°endpoint	PFS		N/A
PFS*	11.1 months	4.6 months	Not reported
OS*	38.0 months	31.6 months	8 months

Approaches to overcome lack of trial head-to-head data

1. Crude indirect comparison:

- Compares
 - lenalidomide arms from pooled MM009/10 trials with
 - melphalan data from observational study (Petrucci 1989)
- Committee identified limitations and implausible results, including:
 - modelled survival benefit LEN+DEX vs. melphalan = 32.4 months whereas
 - trial survival benefit LEN+DEX vs. placebo + DEX = 6.4 months

2. Proxy comparison

- Instead:
 - assume dexamethasone and chemotherapy equally effective and
 - use data from RCTs (as presented in 4th committee meeting)

Committee considerations crude vs. proxy approach

	Crude	Proxy
Risk of bias	High: different populations, confounding	Low: large randomised comparison
Treatments after chemo	Need to adjust for subsequent treatments (company assumed all people had 3^{rd} line lenalidomide if not had before) \rightarrow illogical results (compared with bortezomib)	48% people in dexamethasone arms had 3 rd line lenalidamide→ adjustment unnecessary
Estimating effect size between lenalidomide and chemo	Needed to estimate HRs from median values (statistical approach technically incorrect)	Patient level data available

Assuming clinical effectiveness dexamethasone = chemotherapy

- Facon et al 2006 randomised trial melphalan (n=122) vs. dexamethasone (n=127):
- ERG: Facon showed
 - longer progression free survival with melphalan (22.4 months) than with dexamethasone(12.6 months) and patients not representative of population for appraisal.
 - Longer, non-significant overall survival for melphalan (but underpowered?)
 - Overall ERG preferred proxy method over crude method
- Committee: chemotherapy expected to be more effective than dexamethasone → proxy method favours lenalidomide→ may underestimate ICER vs. melphalan
- Committee concluded to use proxy approach

Lenalidomide vs melphalan proxy approach: results company and ERG

Analysis	ICER
Company base case*	
 ERG base case shorter PFS for dexamethasone (melphalan) company model had implausibly long extrapolated PFS tail for dexamethasone 	
\downarrow PFS \rightarrow \downarrow time on melphalan \rightarrow \downarrow melphalan benefit	

* ERG identified an error in how company incorporated melphalan costs using proxy approach. Company agreed with ERG's correction. Results include correction.

Key committee conclusions in ACD3

Conclusion	ACD
Bortezomib not comparator –	
heard from NHS England retreatment not commissioned	
Cytotoxic chemotherapy is comparator –	4.3
heard from clinical experts that is a treatment option after 1 st relapse	
Modelling based on crude indirect comparison	4.10
High risk of bias, relied on technically incorrect statistical techniques	-4.13
Adjusting for subsequent treatments gave illogical results	
Lacked external validity	
Not suitable for decision making	
Modelling assuming melphalan = dexamethasone (proxy method)	4.14-
preferable, but may underestimate ICER lenalidomide vs. melphalan	
Most plausible ICER, above £	
Did not meet criteria for Cancer Drugs Fund. Clinical evidence from	
MM-009/010 for lenalidomide relatively mature	
(e.g. median overall survival LEN-DEX observed at 50 months MM-009)	
End of life criteria not met – life expectancy >24 months	

Consultation comments

Comments were received from:

- Company no new data or modelling
- UK Myeloma Forum*
- Myeloma UK

Themes

- 1. Relevant 2nd-line comparators after bortezomib
- 2. Crude vs proxy approaches in absence of head-to-head data
- 3. Unmet need


* Comments endorsed by: National Cancer Research Institute; Association of Cancer Physicians; Royal College of Physicians & Royal College of Radiologists

2nd-line comparators after bortezomib

Comparators: chemotherapy

 "...there is absolutely no evidence in the modern era to suggest that conventional chemotherapy is a suitable 2nd line treatment". (UK Myeloma Forum)

Recap of committee conclusions bortezomib as comparator



Comments Comparators: bortezomib 2nd line

- "...change in commissioning for bortezomib retreatment communicated from NHS England appears to be in direct contradiction of NICE TA129" (UK Myeloma Forum)
 - N.B. TA 129 bortezomib 2nd line "having received one prior therapy" preceded TA228 which recommends bortezomib 1st line. Hence bortezomib 'retreatment' as a 2nd treatment not considered in TA129
- "regardless of access to bortezomib a large number of patients would not be suitable to receive 2nd line bortezomib due to poor depth or duration of response to 1st line bortezomib or because of prior bortezomib associated toxicity" (UK Myeloma Forum)
- Does the Committee's conclusion that cytotoxic chemotherapy is a comparator but bortezomib is not a comparator remain the same?

Crude indirect comparison using observational data or using randomised control trial with highdose dexamethasone as a proxy

Company comments: clinical effectiveness data lenalidomide vs. melphalan

- "Celgene agree that the Petrucci 1989 data is uncertain due to the issues highlighted by the committee and ERG in the ACD"
- "Petrucci 1989 data whilst subject to limitations should not be discounted fully as only source of melphalan data available"
- Company sourced data from Haematological Malignancy Research Network (HMRN) registry of northern England, but patients much older than trial patients, little data on patient characteristics making adjusting for covariates impossible

Company comments: crude vs. proxy approach strengths and limitations

Assumption clinical effectiveness dexamethasone = melphalan "uncertain"

- "[Facon 2006] was underpowered and we cannot be certain that melphalan and dexamethasone would have equal outcomes"
- N.B. If not equal, would likely favour lenalidomide

Calculating hazard ratios from median values in naïve approach

- Reiterated: "analysis based on Petrucci 1989 dataset which uses digitised KM curves and the Guyot 2012 algorithm to generate simulated individual patient level dataproduced a very similar ICER (£) to that using the 'crude HR' from the medians"
 N.B. discussed by Committee at 3rd meeting
- Company suggest this method overcomes limitations of 'crude HR'
 - N.B. does not overcome confounding

Company comments: Treatment after lenalidomide in trials (proxy approach) may not reflect UK clinical practice

- 48% patients on dexamethasone in MM trials went on to have lenalidomide 3rd line
- Company's experts say all patients would receive lenalidomide 3rd line (if they did not have it before).
 It is standard of care at 3rd line
 - N.B. might improve survival for melphalan $\rightarrow \uparrow$ ICER?
- Adjusting for 3rd treatments resulted in plausible results lenalidomide vs. melphalan comparison
 - post-progression life years without 3rd line lenalidomide 0.72;
 - with 3rd line lenalidomide 2.73.
 - Reiterated that Committee concerned with lenalidomide vs. bortezomib

• Has the committee seen anything to change its conclusions on the modelling approach? 21

Unmet need

Unmet need

- "(there is an) unnecessary and illogical gap in the myeloma treatment pathway". (Myeloma UK)
- "For myeloma patients at first relapse, who cannot have thalidomide or [bortezomib], there is no available novel agent combination for them to receive [...]
- "As a consequence [patients are] receiving a sub-optimal treatment combination at an extremely critical time in their disease pathway [and] they may not fully benefit from approved NICE guidance further down the treatment pathway". (Myeloma UK)
- "Lenalidomide should be available for 2nd line patients who have previously been treated with bortezomib and for whom further bortezomib is not suitable...[the draft recommendation] is likely to have an adverse impact on patient outcomes" (UK Myeloma Forum)

• What is the Committee's view on the unmet need for 2nd line treatment?

Issues for discussion

- Has the committee seen any new evidence to change its decision:
 - Comparators?
 - Approach to modelling (crude, proxy)?
- Is there an unmet need?